U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07417696) titled 'Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease' on Feb. 11.
Brief Summary: This study aims to evaluate whether the combination of palmitoleic acid with infliximab can improve intestinal mucosal healing in patients with Crohn's disease compared with infliximab alone.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Crohn's Disease
Intervention:
DRUG: Palmitoleic Acid + Infliximab
Patients will be administered oral palmitoleic acid at a dose of 720 mg once daily for 26 consecutive weeks, starting at Week 0.
Concurrent infliximab will be administered intrave...